Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial ; volume:29 ; number:10 ; day:14 ; month:9 ; year:2023 ; pages:2577-2585 ; date:10.2023
Nature medicine ; 29, Heft 10 (14.9.2023), 2577-2585, 10.2023

Creator: Cho, Byoung C.
Kim, Dong-Wan
Spira, Alexander I.
Gomez, Jorge E.
Haura, Eric B.
Kim, Sang-We
Sanborn, Rachel E.
Cho, Eun Kyung
Lee, Ki Hyeong
Minchom, Anna
Lee, Jong-Seok
Han, Ji-Youn
Nagasaka, Misako
Sabari, Joshua K.
Ou, Sai-Hong
Lorenzini, Patricia
Bauml, Joshua M.
Curtin, Joshua C.
Roshak, Amy
Gao, Grace
Xie, John
Thayu, Meena
Knoblauch, Roland E.
Park, Keunchil

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41591-023-02554-7

URN: urn:nbn:de:101:1-2024010508005888111095

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cho, Byoung C.
Kim, Dong-Wan
Spira, Alexander I.
Gomez, Jorge E.
Haura, Eric B.
Kim, Sang-We
Sanborn, Rachel E.
Cho, Eun Kyung
Lee, Ki Hyeong
Minchom, Anna
Lee, Jong-Seok
Han, Ji-Youn
Nagasaka, Misako
Sabari, Joshua K.
Ou, Sai-Hong
Lorenzini, Patricia
Bauml, Joshua M.
Curtin, Joshua C.
Roshak, Amy
Gao, Grace
Xie, John
Thayu, Meena
Knoblauch, Roland E.
Park, Keunchil
SpringerLink (Online service)

Other Objects (12)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer

Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis

Efficacy and safety of osimertinib for leptomeningeal metastases from EGFR-mutant non-small cell lung cancer: a pooled analysis

PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer

Impact of sequential therapy with osimertinib on the overall survival in patients with EGFR-mutant non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer

Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer

Related objects

Reset password